iX Biopharma (SGX:42C) 3-Year Book Growth Rate : -29.30% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma 3-Year Book Growth Rate?

iX Biopharma's Book Value per Share for the quarter that ended in Dec. 2024 was S$0.00.

During the past 12 months, iX Biopharma's average Book Value per Share Growth Rate was -60.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -29.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was -18.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was -10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of iX Biopharma was 26.00% per year. The lowest was -34.80% per year. And the median was -12.75% per year.

Competitive Comparison of iX Biopharma's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where iX Biopharma's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

iX Biopharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

iX Biopharma (SGX:42C) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

iX Biopharma 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of iX Biopharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines